Nasdaq Delisting Deadline and Unremediated Material Weakness Weigh on Rani Therapeutics
RANI sits 86% above its 52-week low of $0.44 on light trading volume (0.4× avg).
Summary
Rani Therapeutics' Q2 10-Q reveals a Nasdaq delisting notice and an ongoing material weakness in internal controls, alongside a cash runway of at least twelve months.
Key Events · Legal and Risk Events · RANI
-
Nasdaq Delisting Notice
Received May 11, 2026, for closing bid price below $1.00 for 30 consecutive days. Compliance deadline is November 9, 2026, with possible 180-day extension if transferred to Nasdaq Capital Market.
-
Material Weakness Unremediated
Disclosure controls and procedures remain ineffective as of June 30, 2026, due to a previously identified material weakness in accounting for complex transactions.
-
Cash Runway
Cash, cash equivalents and marketable securities totaled $53.4 million as of June 30, 2026, expected to fund operations for at least twelve months.
-
Financial Performance
Net loss of $16.4 million for H1 2026, improved from $24.0 million in H1 2025. Contract revenue of $3.4 million from Chugai collaboration.
Analysis · RANI · Life Sciences
The 10-Q reveals that Rani received a Nasdaq delisting notice on May 11, 2026, because its stock traded below $1.00, with a compliance deadline of November 9, 2026. The company also confirms that its material weakness in internal controls remains unremediated. These disclosures appear for the first time in this filing and represent significant governance and listing risks. A cash runway of $53.4 million provides some buffer, but the delisting threat could impair capital raising and liquidity.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RANI was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.8M. The 52-week trading range was $0.44 to $3.87. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.